Imatyle 1000 Tablet contains Imeglimin Hydrochloride 1000mg, a next-generation oral antidiabetic agent designed to improve glycemic control in patients with Type 2 Diabetes Mellitus (T2DM). It works by targeting the mitochondrial bioenergetic pathway, enhancing insulin sensitivity, reducing hepatic glucose production, and increasing pancreatic beta-cell function.
This innovative molecule is increasingly preferred for patients requiring improved glucose management without significant risk of hypoglycemia.
Imatyle 1000 Tablet belongs to the diabetology and chronic care therapy segment, commonly prescribed by diabetologists, physicians, and endocrinologists.
For PCD pharma franchise partners, distributors, and exporters, Imatyle 1000 offers a high-demand portfolio advantage in the rapidly growing diabetes management market. It is available for bulk supply, contract manufacturing, PCD franchise with monopoly rights, institutional tenders, and international export.